iBio (IBIO) Net Margin (2011 - 2025)

iBio (IBIO) posted quarterly Net Margin of 5670.0% for Q3 2025, down 134.39% quarter-over-quarter from 2419.0% in Q2 2025.

iBio (IBIO) Net Margin (2011 - 2025) Analysis & Trends

iBio (IBIO) has reported Net Margin for 15 consecutive years, with 5670.0% the latest figure, recorded in Q3 2025.

In Q3 2025, Net Margin changed N/A year-over-year to 5670.0%; the TTM figure through Mar 2026 stood at 9077.0% (down 434473.0% YoY), while the FY2025 annual figure was 20389.25%, down 1618303.0% from the prior year.
Net Margin retreated to 5670.0% in Q3 2025 per IBIO's latest filing, from 2419.0% in the prior quarter.
Across five years, Net Margin topped out at 10.39% in Q2 2021 and bottomed at 6254.76% in Q3 2021.
Historically, Net Margin has averaged 2460.8% across 5 years, with a median of 2182.0% in 2024.
On a YoY basis, Net Margin climbed as much as 392874 bps in 2021 and fell as far as 440135 bps in 2021.
iBio's Net Margin stood at 6254.76% in 2021, then soared by 89 bps to 688.33% in 2022, then tumbled by 95 bps to 1344.0% in 2023, then plunged by 62 bps to 2182.0% in 2024, then tumbled by 160 bps to 5670.0% in 2025.
Business Quant data shows IBIO's Net Margin at 5670.0% in Q3 2025, 2419.0% in Q2 2025, and 2182.0% in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.23%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	31.16%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	12.74%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-3.12%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-16.51%
10	iBio	175.21 Mn	175.21 Mn	-	-

Download Data